• 3-Hydroxybutyrate (BHBA): Unlocking Neuroprotection Pathways

  2026-07-04

  This thought-leadership article explores the mechanistic underpinnings and translational impact of 3-hydroxybutyrate (BHBA) as a central ketone body signaling molecule in neuroprotection. Drawing on cutting-edge research, it provides strategic guidance for translational researchers implementing BHBA in metabolic, epigenetic, and neurodegenerative disease models. The article highlights BHBA’s dual role as a fatty acid β-oxidation metabolite and class I histone deacetylase inhibitor, its protocol optimization, and the evolving competitive landscape for in vitro ketosis models, with a focus on advanced stroke research and ferroptosis inhibition.

• Intravesical p21 mRNA-LNP Therapy for Bladder Cancer: Advanc

  2026-07-03

  This article reviews a landmark study demonstrating the efficacy of intravesical delivery of p21 mRNA-loaded lipid nanoparticles as a targeted tumor suppressor replacement therapy for bladder cancer. The research provides mechanistic evidence for restored cell cycle control and highlights the translational potential of localized mRNA therapies.

• Anlotinib Hydrochloride: Precision Angiogenesis Inhibition U

  2026-07-03

  Discover how Anlotinib hydrochloride, a multi-target tyrosine kinase inhibitor, enables precise angiogenesis inhibition for advanced cancer research. This article delivers a deep mechanistic analysis and practical assay guidance beyond standard workflows.

• Olsalazine Sodium: Mechanistic Insights for Colorectal Cance

  2026-07-02

  Explore the mechanistic basis and advanced applications of Olsalazine Sodium as a mesalamine dimer in colorectal cancer research. This article uniquely examines transporter biology and xenobiotic handling, offering actionable insights for inflammation and cancer assay design.

• Fosinopril Sodium: Applied Workflows for Cardiovascular Rese

  2026-07-02

  Fosinopril sodium, a third-generation phosphinic acid ACE inhibitor from APExBIO, stands out for its dual renal-hepatic elimination and high oral bioavailability, offering robust, reproducible outcomes in hypertension and cardiovascular disease models. This guide translates reference-backed insights into actionable experimental workflows, troubleshooting tips, and optimized protocol parameters for advanced bench research.

• Ciclesonide: Prodrug Activation and Potency in Asthma Resear

  2026-07-01

  Ciclesonide is a prodrug glucocorticoid used in asthma and allergic rhinitis research, displaying rapid conversion to the highly potent desisobutyryl-ciclesonide. Its unique pharmacokinetic and receptor-binding profile enables targeted anti-inflammatory action in preclinical models. This article details evidence, use parameters, and common misconceptions for robust bench application.

• Technical Guidance: HyperPFU™ High-Fidelity DNA Polymerase i

  2026-07-01

  HyperPFU™ high-fidelity DNA polymerase is designed for accurate PCR amplification of long, GC-rich, or otherwise difficult DNA templates, addressing challenges where standard enzymes fail due to low fidelity or processivity. It is best suited for workflows requiring blunt-ended, high-fidelity PCR products, and should not be used for protocols needing 3'-A overhangs or sticky ends.

• A-1210477: Applied Workflows for MCL-1 Inhibition in Cancer

  2026-06-30

  A-1210477 stands out as a selective, high-affinity MCL-1 inhibitor that enables precise dissection of mitochondrial apoptosis in MCL-1-dependent cancer models. This guide details experimental workflows, troubleshooting strategies, and practical optimizations to maximize assay reliability and biological insight.

• Genistein in Precision Cancer Research: Mechanisms and Proto

  2026-06-30

  Explore Genistein as a selective protein tyrosine kinase inhibitor and its emerging role in targeted cancer chemoprevention. This article delivers in-depth analysis and protocol guidance, uniquely integrating cytoskeleton-dependent autophagy insights for advanced assay design.

• Omeprazole (A2845): Protocols for H+,K+-ATPase Inhibition St

  2026-06-29

  Omeprazole (SKU A2845) is a potent H+,K+-ATPase inhibitor optimized for controlled laboratory studies of gastric acid secretion and antiulcer mechanisms. It is not suitable for diagnostic or therapeutic applications and should be used only in research workflows with appropriate handling and QC measures.

• Technical Use of HyperPFU™ High-Fidelity DNA Polymerase (K10

  2026-06-29

  HyperPFU™ high-fidelity DNA polymerase addresses the technical challenges of PCR amplification for long, GC-rich, or otherwise difficult DNA fragments, offering high accuracy and robust performance. It is not suitable for applications requiring 3'-A overhangs or sticky-end ligation, making it best reserved for workflows demanding blunt-ended, high-fidelity PCR products.

• ZK53: Human Mitochondrial Serine Protease ClpP Activator in

  2026-06-28

  ZK53 delivers precise, potent activation of human mitochondrial ClpP, enabling targeted disruption of tumor cell metabolism with minimal off-target effects. Its unique specificity and robust in vitro and in vivo performance make it a transformative tool for mitochondrial dysfunction, ferroptosis sensitization, and advanced cancer modeling.

• FGF2-Driven BCL-2 Upregulation Enables Non-Cell Autonomous A

  2026-06-27

  This study uncovers a non-cell autonomous mechanism where apoptotic stress prompts FGF2 release, driving MEK-ERK-dependent upregulation of anti-apoptotic BCL-2 proteins in neighboring cells. These findings provide new insight into how cancer cells and damaged tissues transiently resist apoptosis, impacting therapeutic strategies targeting the BCL-2 family.

• Sabutoclax: Applied Pan-Bcl-2 Inhibitor Workflows in Cancer

  2026-06-26

  Sabutoclax, a potent pan-Bcl-2 inhibitor, enables robust apoptosis induction workflows across diverse cancer models. This article translates quantitative efficacy data and reference study innovations into practical protocols and troubleshooting strategies, empowering researchers to accelerate translational oncology insights.

• A-1210477: Selective MCL-1 Inhibitor for Cancer Research

  2026-06-26

  A-1210477 is a potent, selective MCL-1 inhibitor with nanomolar affinity, enabling precise investigation of apoptosis regulation in cancer cells. Its high specificity and in vitro efficacy make it a critical tool for dissecting MCL-1-dependent survival mechanisms, though its pharmacokinetic features limit in vivo applications.

16270 records 1/1085 page Next 12345 下5页 Last page